The molecular biology of lung cancer.

A. F. Gazdar

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Lung cancer arises after a series of morphological changes, which take several years to progress from normal epithelium to invasive cancer. The morphological changes progress from hyperplasia, to metaplasia, to dysplasia, to carcinoma in situ, to invasive cancer and finally to metastatic cancer. Multiple molecular changes have been documented in lung cancers, both small cell (SCLC) and non-small cell (NSCLC) types. The number of changes has been estimated to be in double digits. These changes include activation of dominant oncogenes myc family, (K-ras and neu genes), as well as loss of recessive growth regulatory genes or anti-oncogenes (p53, and RB as well as unidentified gene or genes on chromosome 3). However, cytogenetic and molecular genetic studies indicate that multiple other specific sites of actual or potential DNA loss may be present in lung cancers. Other changes may include development of drug resistance, and production of growth factors and their receptors. It is tempting to associate specific molecular changes with specific morphological changes, as has been attempted in the colon. However, because of the difficulties in serially sampling the respiratory tract, such studies have not been performed to date. Documentation of molecular changes in premalignant lesions and prospective studies of their prognostic effects will be necessary for the design of rational chemoprevention trials.

Original languageEnglish (US)
Pages (from-to)239-245
Number of pages7
JournalTohoku Journal of Experimental Medicine
Volume168
Issue number2
StatePublished - Oct 1992

Fingerprint

Molecular biology
Molecular Biology
Lung Neoplasms
Genes
erbB-2 Genes
Neoplasms
myc Genes
Chromosomes, Human, Pair 3
ras Genes
Growth Factor Receptors
Carcinoma in Situ
Small Cell Lung Carcinoma
Chemoprevention
Metaplasia
Regulator Genes
Tumor Suppressor Genes
Drug Resistance
Cytogenetics
Documentation
Respiratory System

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The molecular biology of lung cancer. / Gazdar, A. F.

In: Tohoku Journal of Experimental Medicine, Vol. 168, No. 2, 10.1992, p. 239-245.

Research output: Contribution to journalArticle

Gazdar, AF 1992, 'The molecular biology of lung cancer.', Tohoku Journal of Experimental Medicine, vol. 168, no. 2, pp. 239-245.
Gazdar, A. F. / The molecular biology of lung cancer. In: Tohoku Journal of Experimental Medicine. 1992 ; Vol. 168, No. 2. pp. 239-245.
@article{d859703aff03445fb38dd64ac062422e,
title = "The molecular biology of lung cancer.",
abstract = "Lung cancer arises after a series of morphological changes, which take several years to progress from normal epithelium to invasive cancer. The morphological changes progress from hyperplasia, to metaplasia, to dysplasia, to carcinoma in situ, to invasive cancer and finally to metastatic cancer. Multiple molecular changes have been documented in lung cancers, both small cell (SCLC) and non-small cell (NSCLC) types. The number of changes has been estimated to be in double digits. These changes include activation of dominant oncogenes myc family, (K-ras and neu genes), as well as loss of recessive growth regulatory genes or anti-oncogenes (p53, and RB as well as unidentified gene or genes on chromosome 3). However, cytogenetic and molecular genetic studies indicate that multiple other specific sites of actual or potential DNA loss may be present in lung cancers. Other changes may include development of drug resistance, and production of growth factors and their receptors. It is tempting to associate specific molecular changes with specific morphological changes, as has been attempted in the colon. However, because of the difficulties in serially sampling the respiratory tract, such studies have not been performed to date. Documentation of molecular changes in premalignant lesions and prospective studies of their prognostic effects will be necessary for the design of rational chemoprevention trials.",
author = "Gazdar, {A. F.}",
year = "1992",
month = "10",
language = "English (US)",
volume = "168",
pages = "239--245",
journal = "Tohoku Journal of Experimental Medicine",
issn = "0040-8727",
publisher = "Tohoku University Medical Press",
number = "2",

}

TY - JOUR

T1 - The molecular biology of lung cancer.

AU - Gazdar, A. F.

PY - 1992/10

Y1 - 1992/10

N2 - Lung cancer arises after a series of morphological changes, which take several years to progress from normal epithelium to invasive cancer. The morphological changes progress from hyperplasia, to metaplasia, to dysplasia, to carcinoma in situ, to invasive cancer and finally to metastatic cancer. Multiple molecular changes have been documented in lung cancers, both small cell (SCLC) and non-small cell (NSCLC) types. The number of changes has been estimated to be in double digits. These changes include activation of dominant oncogenes myc family, (K-ras and neu genes), as well as loss of recessive growth regulatory genes or anti-oncogenes (p53, and RB as well as unidentified gene or genes on chromosome 3). However, cytogenetic and molecular genetic studies indicate that multiple other specific sites of actual or potential DNA loss may be present in lung cancers. Other changes may include development of drug resistance, and production of growth factors and their receptors. It is tempting to associate specific molecular changes with specific morphological changes, as has been attempted in the colon. However, because of the difficulties in serially sampling the respiratory tract, such studies have not been performed to date. Documentation of molecular changes in premalignant lesions and prospective studies of their prognostic effects will be necessary for the design of rational chemoprevention trials.

AB - Lung cancer arises after a series of morphological changes, which take several years to progress from normal epithelium to invasive cancer. The morphological changes progress from hyperplasia, to metaplasia, to dysplasia, to carcinoma in situ, to invasive cancer and finally to metastatic cancer. Multiple molecular changes have been documented in lung cancers, both small cell (SCLC) and non-small cell (NSCLC) types. The number of changes has been estimated to be in double digits. These changes include activation of dominant oncogenes myc family, (K-ras and neu genes), as well as loss of recessive growth regulatory genes or anti-oncogenes (p53, and RB as well as unidentified gene or genes on chromosome 3). However, cytogenetic and molecular genetic studies indicate that multiple other specific sites of actual or potential DNA loss may be present in lung cancers. Other changes may include development of drug resistance, and production of growth factors and their receptors. It is tempting to associate specific molecular changes with specific morphological changes, as has been attempted in the colon. However, because of the difficulties in serially sampling the respiratory tract, such studies have not been performed to date. Documentation of molecular changes in premalignant lesions and prospective studies of their prognostic effects will be necessary for the design of rational chemoprevention trials.

UR - http://www.scopus.com/inward/record.url?scp=0026937922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026937922&partnerID=8YFLogxK

M3 - Article

C2 - 1306309

AN - SCOPUS:0026937922

VL - 168

SP - 239

EP - 245

JO - Tohoku Journal of Experimental Medicine

JF - Tohoku Journal of Experimental Medicine

SN - 0040-8727

IS - 2

ER -